Cancer vaccine shows sustained improvement in survival rates
Drug Discovery World
JUNE 6, 2024
The combination therapy was also shown to reduce the risk of distant metastasis or death by 62% compared to Keytruda alone in these patients. The global Phase III clinical trial is being led by University College London Hospitals NHS Foundation Trust in the UK and will include around 1,100 people.
Let's personalize your content